At present, REZDIFFRA stands as the only approved NASH drug to battle the devastating disease. This once-daily, oral THR-β agonist received a fast-track nod from the US FDA in March 2024, thanks to the impressive outcomes of the Phase III MAESTRO-NASH trial. But with one trailblazer already in the ring, the race is heating up—now every other contender is gunning to be the next in line, eager to claim the coveted title of the second approved NASH therapy. The game is on!
Want the full scoop on REZDIFFRA’s rise? Check out our blog @ REZDIFFRA’s Trailblazing Journey in NASH Treatment
The Race for the Next Best NASH Drug
As the obesity and metabolic disorder cris...
